<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518192</url>
  </required_header>
  <id_info>
    <org_study_id>EM-DC</org_study_id>
    <nct_id>NCT01518192</nct_id>
  </id_info>
  <brief_title>Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome</brief_title>
  <official_title>Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Slovenian Research Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  While doxycycline is a standard antibiotic for treatment of erythema migrans in Europe
           as well as in the USA, the effectiveness of cefuroxime axetil in the treatment of adult
           patients with erythema migrans has been assessed only in the USA where the causative
           agent of Lyme disease is Borrelia burgdorferi, but not in Europe where the main
           etiologic agents are B. afzelii and B. garinii.

        -  Controversy exists over the significance and even the existence of post-Lyme disease
           symptoms because of the high rate of similar background symptoms in the general
           population.

      Purpose:

      The two main purposes of this European, prospective clinical trial in which doxycycline and
      cefuroxime axetil are compared in the treatment of adult patients with erythema migrans and
      which included a control group to address the significance of post-Lyme disease symptoms are:

        -  To assess and compare the effectiveness of doxycycline and cefuroxime axetil in the
           treatment of erythema migrans using clinical and bacteriological criteria
           (noninferiority testing approach), and

        -  to compare the frequency of post-Lyme disease symptoms in adult patients treated for EM
           with antibiotics and the frequency of similar symptoms in control subjects without Lyme
           disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sample size

      Decisions were based on the following:

        1. Number of patients with erythema migrans treated with doxycycline and cefuroxime axetil
           was determined assuming no difference in treatment outcome will be detected
           (non-inferiority testing).

        2. The decision for a larger sample sizes than needed for 1. was done with the intention to
           evaluate the secondary outcome measure, i.e., to assess the difference between the
           frequency of new or increased symptoms in patients treated for early Lyme disease and
           the occurrence of the same symptoms in control subjects.

             1. We assumed that the outcomes in the two treatment groups will be comparable and
                that the patients could be combined for further analysis.

             2. To obtain a control group from the same geographical area, each patient was asked
                if she or he had a family member or friend who was within 5 years of her or his age
                and who was without a history of Lyme borreliosis. These persons were approached by
                a short written explanation of the investigation, containing also a request for
                their participation. We assumed that we will be able to get a corresponding control
                person not for all but for approximately 80-90% of patients.

             3. Under the assumption that approximately 15% of an estimated 200 patients would have
                new or increased symptoms at &gt;6 months after enrollment into the study, a control
                group of 165 subjects would be sufficient to detect a &gt;10 percentage point lower
                rate of new or increased symptoms in controls compared with patients at the 0.05
                level (2-sided) with &gt;90% power. To comply with drop outs at different time points
                we assessed that 280 patients and 230 controls should be included at baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days</measure>
    <time_frame>at 14 days post inclusion</time_frame>
    <description>Number of patients with objective manifestations of Lyme disease(persistence of erythema migrans or any of the extracutaneous-cardiac, nervous or skeletal-Lyme disease manifestations)and/or with post-Lyme disease symptoms in patients treated for solitary erythema migrans at 14 days post inclusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>at 14 days</time_frame>
    <description>Number of patients reporting adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 2 Months</measure>
    <time_frame>2 months</time_frame>
    <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 2 months post inclusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 6months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 6 months post inclusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 12 months post inclusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New or Increased Symptoms Since Erythema Migrans in Patients and Controls at 6 Months.</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the number patients and controls with new or increased symptoms since erythema migrans at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or Increased Symptoms Since Erythema Migrans in Patients Controls at 12 Months.</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the number of patients and controls with new or increased symptoms since erythema migrans at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected Subjective Symptoms in Patients and Control Subjects</measure>
    <time_frame>Examination at 12 months</time_frame>
    <description>Comparison of the number of patients and controls with selected 8 symptoms (fatigue, arthralgias, myalgias, headache, paresthesias, dizziness, irritability, or nausea) within the preceding week, irrespective of whether they were new or increased since erythema migrans.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">544</enrollment>
  <condition>Erythema Migrans</condition>
  <condition>Post-Lyme Disease Symptoms</condition>
  <arm_group>
    <arm_group_label>1Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Cefuroxime axetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>100 mg bid; 15 days</description>
    <arm_group_label>1Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefuroxime axetil</intervention_name>
    <description>500 mg bid; 15 days</description>
    <arm_group_label>2 Cefuroxime axetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 15 or more years old

          -  with typical erythema migrans

          -  evaluated between 6/06 and 9/06

          -  evaluated at the Lyme Disease Outpatient Clinic, University Medical Center Ljubljana,
             Slovenia.

        Exclusion Criteria:

          -  history of Lyme disease in the past

          -  pregnancy

          -  lactation

          -  immunocompromising condition

          -  history of a serious adverse reaction to a beta-lactam or tetracycline drug

          -  receiving an antibiotic with known anti-borrelial activity within 10 days

          -  multiple erythema migrans lesions or an extracutaneous manifestation of Lyme disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Da≈°a Cerar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franc Strle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <results_first_submitted>June 28, 2010</results_first_submitted>
  <results_first_submitted_qc>December 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2012</results_first_posted>
  <last_update_submitted>December 18, 2011</last_update_submitted>
  <last_update_submitted_qc>December 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Franc Strle</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>erythema migrans</keyword>
  <keyword>doxycycline</keyword>
  <keyword>cefuroxime axetil</keyword>
  <keyword>post-Lyme disease symptoms</keyword>
  <keyword>background symptoms in general population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients with typical erythema migrans, examined in the period from June to September 2006 at Lyme Disease Outpatient Clinic, University Medical Center Ljubljana, Slovenia</recruitment_details>
      <pre_assignment_details>113/398 patients were ineligible due to:
receiving antibiotic with known anti-borrelial activity (73)
multiple erythema migrans (16)
history of Lyme disease (12)
immunocompromising condition (4)
serious adverse reaction to study drugs (3)
pregnancy or lactation (4)
erythema migrans accompanied by meningitis (1)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxycycline</title>
          <description>Patients were assigned to receive a 15-day oral treatment with doxycycline 100 mg twice daily.
At baseline and at 14 days, 2, 6, and 12 months thereafter, patients were interviewed and examined. At baseline, a skin biopsy specimen was cultured; this procedure was repeated 2-3 months later in patients with a positive culture.</description>
        </group>
        <group group_id="P2">
          <title>Cefuroxime Axetil</title>
          <description>Patients were assigned to receive a 15-day oral treatment with cefuroxime axetil 500 mg twice daily.
At baseline and at 14 days, 2, 6, and 12 months thereafter, patients were interviewed and examined. At baseline, a skin biopsy specimen was cultured; this procedure was repeated 2-3 months later in patients with a positive culture.</description>
        </group>
        <group group_id="P3">
          <title>Controls</title>
          <description>patients' family members or friends without a history of Lyme disease</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxycycline</title>
          <description>Patients were assigned to receive a 15-day oral treatment with either doxycycline 100 mg or cefuroxime axetil 500 mg twice daily, by alternating treatment regimens each week.
Evaluations:
At baseline and at 14 days, 2, 6, and 12 months thereafter, patients were interviewed and examined. At baseline, a skin biopsy specimen was cultured as previously described; this procedure was repeated 2-3 months later in patients with a positive culture.</description>
        </group>
        <group group_id="B2">
          <title>Cefuroxime Axetil</title>
          <description>Patients were assigned to receive a 15-day oral treatment with either doxycycline 100 mg or cefuroxime axetil 500 mg twice daily, by alternating treatment regimens each week.
Evaluations:
At baseline and at 14 days, 2, 6, and 12 months thereafter, patients were interviewed and examined. At baseline, a skin biopsy specimen was cultured as previously described; this procedure was repeated 2-3 months later in patients with a positive culture.</description>
        </group>
        <group group_id="B3">
          <title>Controls</title>
          <description>To obtain a control group from the same geographical area, each patient was asked if he/she had a family member or friend who was within 5 years of his/her age and had no history of Lyme disease (two of the potential control subjects were excluded due to this reason), and was not pregnant, lactating or immunocompromised.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="259"/>
            <count group_id="B4" value="544"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="14.6" lower_limit="17" upper_limit="85"/>
                    <measurement group_id="B2" value="51.5" spread="14.9" lower_limit="19" upper_limit="82"/>
                    <measurement group_id="B3" value="52" lower_limit="15" upper_limit="85"/>
                    <measurement group_id="B4" value="52.5" spread="14.9" lower_limit="15" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="286.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="258.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="544.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days</title>
        <description>Number of patients with objective manifestations of Lyme disease(persistence of erythema migrans or any of the extracutaneous-cardiac, nervous or skeletal-Lyme disease manifestations)and/or with post-Lyme disease symptoms in patients treated for solitary erythema migrans at 14 days post inclusion</description>
        <time_frame>at 14 days post inclusion</time_frame>
        <population>All participants who followed the protocol were eligible for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>doxycycline 100 mg twice daily for 15 days</description>
          </group>
          <group group_id="O2">
            <title>Cefuroxime Axetil</title>
            <description>cefuroxime axetil 500 mg twice daily for 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days</title>
          <description>Number of patients with objective manifestations of Lyme disease(persistence of erythema migrans or any of the extracutaneous-cardiac, nervous or skeletal-Lyme disease manifestations)and/or with post-Lyme disease symptoms in patients treated for solitary erythema migrans at 14 days post inclusion</description>
          <population>All participants who followed the protocol were eligible for analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New or Increased Symptoms Since Erythema Migrans in Patients and Controls at 6 Months.</title>
        <description>Comparison of the number patients and controls with new or increased symptoms since erythema migrans at 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>all participants who followed the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>patients with new or increased symptoms since erythema migrans at 6 months post inclusion</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>controls with new or increased symptoms since enrollment at 6 months post inclusion</description>
          </group>
        </group_list>
        <measure>
          <title>New or Increased Symptoms Since Erythema Migrans in Patients and Controls at 6 Months.</title>
          <description>Comparison of the number patients and controls with new or increased symptoms since erythema migrans at 6 months.</description>
          <population>all participants who followed the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Number of patients reporting adverse events</description>
        <time_frame>at 14 days</time_frame>
        <population>All participants who followed the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>doxycycline 100 mg twice daily for 15 days</description>
          </group>
          <group group_id="O2">
            <title>Cefuroxime Axetil</title>
            <description>cefuroxime axetil 500 mg twice daily for 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of patients reporting adverse events</description>
          <population>All participants who followed the protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 2 Months</title>
        <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 2 months post inclusion</description>
        <time_frame>2 months</time_frame>
        <population>all participants who followed the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>doxycycline 100 mg twice daily for 15 days</description>
          </group>
          <group group_id="O2">
            <title>Cefuroxime Axetil</title>
            <description>cefuroxime axetil 500 mg twice daily for 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 2 Months</title>
          <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 2 months post inclusion</description>
          <population>all participants who followed the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 6months</title>
        <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 6 months post inclusion</description>
        <time_frame>6 months</time_frame>
        <population>all participants who followed the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>doxycycline 100 mg twice daily for 15 days</description>
          </group>
          <group group_id="O2">
            <title>Cefuroximew Axetil</title>
            <description>cefuroxime axetil 500 mg twice daily for 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 6months</title>
          <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 6 months post inclusion</description>
          <population>all participants who followed the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 12 Months</title>
        <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 12 months post inclusion</description>
        <time_frame>12 months</time_frame>
        <population>all participants who followed the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>doxycycline 100 mg twice daily for 15 days</description>
          </group>
          <group group_id="O2">
            <title>Cefuroxime Axetil</title>
            <description>cefuroxime axetil 500 mg twice daily for 15 days</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 12 Months</title>
          <description>Number of patients with objective Lyme disease manifestations and/or post-Lyme disease symptoms in patients treated for solitary erythema migrans at 12 months post inclusion</description>
          <population>all participants who followed the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New or Increased Symptoms Since Erythema Migrans in Patients Controls at 12 Months.</title>
        <description>Comparison of the number of patients and controls with new or increased symptoms since erythema migrans at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>all participants who followed the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>patients with new or increased symptoms since erythema migrans at 12 months post inclusion</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>controls with new or increased symptoms since erythema migrans at 12 months post inclusion</description>
          </group>
        </group_list>
        <measure>
          <title>New or Increased Symptoms Since Erythema Migrans in Patients Controls at 12 Months.</title>
          <description>Comparison of the number of patients and controls with new or increased symptoms since erythema migrans at 12 months.</description>
          <population>all participants who followed the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Selected Subjective Symptoms in Patients and Control Subjects</title>
        <description>Comparison of the number of patients and controls with selected 8 symptoms (fatigue, arthralgias, myalgias, headache, paresthesias, dizziness, irritability, or nausea) within the preceding week, irrespective of whether they were new or increased since erythema migrans.</description>
        <time_frame>Examination at 12 months</time_frame>
        <population>all participants who followed the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>patients with selected subjective symptoms at 12 months post inclusion</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>controls with selected subjective symptoms at 12 months post inclusion</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Subjective Symptoms in Patients and Control Subjects</title>
          <description>Comparison of the number of patients and controls with selected 8 symptoms (fatigue, arthralgias, myalgias, headache, paresthesias, dizziness, irritability, or nausea) within the preceding week, irrespective of whether they were new or increased since erythema migrans.</description>
          <population>all participants who followed the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Doxycycline</title>
          <description>Patients were assigned to receive a 15-day oral treatment with doxycycline 100 mg twice daily.
At baseline and at 14 days, 2, 6, and 12 months thereafter, patients were interviewed and examined. At baseline, a skin biopsy specimen was cultured; this procedure was repeated 2-3 months later in patients with a positive culture.</description>
        </group>
        <group group_id="E2">
          <title>Cefuroxime Axetil</title>
          <description>Patients were assigned to receive a 15-day oral treatment with cefuroxime axetil 500 mg twice daily.
At baseline and at 14 days, 2, 6, and 12 months thereafter, patients were interviewed and examined. At baseline, a skin biopsy specimen was cultured; this procedure was repeated 2-3 months later in patients with a positive culture.</description>
        </group>
        <group group_id="E3">
          <title>Controls</title>
          <description>patients' family members or friends without a history of Lyme disease</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.7</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="145"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Medical explanation besides Lyme disease of the symptoms in patients was based on history and physical examination, therefore some other medical explanations might have been missed. With regard to controls this was even more likely.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Franc Strle</name_or_title>
      <organization>Department of Infectious Diseases, University Medical Center Ljubljana</organization>
      <phone>+386 1 522 2610</phone>
      <email>franc.strle@kclj.si</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

